secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2022-02-09T23:59:59+00:00
Accession:  0001564590-22-004406
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics Q4 net loss $12.4M; clinical hold on VK0214; cash $202.1M
-----------------------------------------------------------------------------

- Net loss $12.4M ($0.16/share) for Q4 2021 vs $10.9M ($0.15) year ago; FY net loss $55.0M ($0.71) vs $39.5M ($0.54).
- Cash, equivalents, short-term investments $202.1M at Dec 31, 2021, down from $248.4M a year ago.
- FDA placed Phase 1b trial of VK0214 (X-ALD) on clinical hold; expects to submit requested preclinical data in Q2 2022.
- Phase 1 trial of dual GLP-1/GIP agonist VK2735 initiated; data expected in 2H22.
- Phase 2b VOYAGE trial of VK2809 for NASH continuing enrollment; initial data expected by end of 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000156459022004406/0001564590-22-004406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000156459022004406/vktx-8k_20220209.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-004406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer